{"id":21404,"date":"2024-06-05T09:16:24","date_gmt":"2024-06-05T09:16:24","guid":{"rendered":"https:\/\/clinlabint.com\/?p=21404"},"modified":"2024-05-28T09:19:59","modified_gmt":"2024-05-28T09:19:59","slug":"bio-rad-to-collaborate-with-oncocyte-to-commercialize-transplant-monitoring-with-droplet-digital-pcr","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/bio-rad-to-collaborate-with-oncocyte-to-commercialize-transplant-monitoring-with-droplet-digital-pcr\/","title":{"rendered":"Bio-Rad to collaborate with Oncocyte to commercialize transplant monitoring with Droplet Digital PCR"},"content":{"rendered":"
\n

\r\n\"Forum<\/a>\r\n<\/div><\/p>\n<\/div><\/section><\/div>

\r\n\r\n\"\"<\/a>\r\n<\/div><\/p>\n<\/div><\/section>
\n

Bio-Rad to collaborate with Oncocyte to commercialize transplant monitoring with Droplet Digital PCR<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, will collaborate with Oncocyte Corporation, a precision diagnostics company, to develop and commercialize transplant monitoring products using Bio-Rad\u2019s Droplet Digital PCR (ddPCR) instruments and reagents.<\/h3>\n

<\/p>\n

Under the terms of the agreement, Bio-Rad has committed to participate in a private placement of Oncocyte\u2019s equity and has secured exclusive commercial rights in certain markets to commercialize Oncocyte\u2019s assay for transplant monitoring research using Bio-Rad\u2019s QX600 ddPCR System.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

Transplanted organs release cell-free DNA into the bloodstream of the recipient. This donor-derived cell-free DNA (dd-cfDNA1) is a sensitive biomarker for organ health that requires only a simple blood draw. The novel approach developed by the team at Oncocyte allows the assay to be applied to clinical research of both recent and non-recent transplants. The utility of the ddPCR-based approach has been well demonstrated, including in a prospective, observational, multicentre cohort trial published in 2017, which showed earlier and more sensitive discrimination of liver transplant patients with acute rejection, compared to conventional liver functional test methods2.<\/p>\n

Oncocyte\u2019s transplant monitoring assays and the Bio-Rad QX600 ddPCR System provide a highly sensitive and decentralized solution that could provide a more attractive alternative for laboratories that currently rely on centralized next-generation sequencing (NGS) test providers.<\/p>\n

Commenting on the collaboration, Simon May, EVP and President of Life Sciences at Bio-Rad Laboratories, said: \u201cThis collaboration advances Bio-Rad\u2019s strategy to establish Droplet Digital PCR as a foundational technology by providing researchers and laboratories with high-value assays across a variety of life science applications. We believe that Oncocyte\u2019s transplant monitoring assays and the Bio-Rad QX600 ddPCR System solution for the noninvasive measurement and quantification of key biomarkers used in solid tissue transplant monitoring research has the potential to advance science and save lives.\u201d<\/p>\n

To learn more about Bio-Rad\u2019s ddPCR technology visit: www.bio-rad.com\/qx600system<\/a>.<\/p>\n

References:<\/strong><\/em>
\n1. Donor-derived cell-free DNA (dd-cfDNA) is also known as graft-derived cell-free DNA (GcfDNA)<\/em>
\n2. Sch\u00fctz E et al. (2017). Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. PLoS Med 14, e1002286.<\/em><\/p>\n<\/div><\/section>
\n